SEQ-400
For recurrent UTIs
Our lead program, SEQ-400, is a FimH vaccine for the prevention of recurrent urinary tract infections (UTIs).
SEQ-1274 Drug Platform
A novel molecule class to inhibit ovarian and other cancer cell growth
SEQ-1274 is a chemically synthesized analogue of a new compound discovered using our platform technology.1 We are developing this and other novel small molecules from this platform as a potential treatment for serious, high-grade ovarian and potentially other cancers.
1. "Isolation and Identification of the Novel Tubulin Polymerization Inhibitor Bifidenone," R.B. Williams, et al,Journal of Natural Products, Article ASAP, DOI: 10.1021/acs.jnatprod.6b00893).
| Indication or Program | Preclinical | Phase 1 | Phase 2 | Phase 2/3 | Market |
|---|---|---|---|---|---|
SEQ-1274 drug platformOvarian and Other Cancers |
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 2/3 Phase not started
|
Market Phase not started
|
Ovarian cancer market overview
~21,000
Estimated number of women who will be diagnosed in the U.S.
~13,000
Estimated number of deaths that will occur due to ovarian cancer
<50%
Overall 5-year survival rate for ovarian cancer
Source
Source: American Cancer Society. Cancer Facts & Figures 2022.
How it works
An inside look at SEQ-1274
SEQ-1274 is a novel microtubule inhibitor that binds to the colchicine-binding site on tubulin, a protein and main component for forming microtubules (hollow fibers that act as skeletal structures for living cells).
SEQ-1274 and analogs are potently active against over 50 human cancer cell lines (including ovarian, lung, breast, colon, central nervous system (CNS), melanoma, prostate, renal, and uterine), including several taxane-resistant cell lines. It is 5-1000 times more active than paclitaxel in a number of these cell lines.
Preclinical studies
SEQ-1274 compared to paclitaxel (taxane) in animal tumor models
SEQ-1274 has demonstrated efficacy in animal tumor models performed at four independent laboratories. Washington University researchers led by Dr. Katherine C. Fuh recently examined the potential of SEQ-1274 in the arsenal against ovarian and uterine cancers. The group compared SEQ-1274 to paclitaxel, a microtubule inhibitor, and found that SEQ-1274 was more active against ovarian and uterine cancer cell lines and that SEQ-1274 can decrease the expression of AXL, a protein contributing to paclitaxel resistance.
Mills, K. A., Roach, S. T., Quinn, J. M., Guo, L., Beck, H. M., Lomonosova, E., Ilivicky, A. R., Starks, C. M., Lawrence, J. A., Hagemann, A. R., McCourt, C., Thaker, P. H., Powell, M. A., Mutch, D. G., & Fuh, K. C. (2018). SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth. Gynecologic Oncology, 151(2), 337–344. https://doi.org/10.1016/j.ygyno.2018.08.008
Development & milestones
SEQ-1274 analogs for ovarian cancer timeline
Optimization for IND-enabling preclinical safety studies will be completed in 2024, and we anticipate entering clinical trials in 2025.
Novel Small Molecule Drug Platform
For lung infections in cystic fibrosis patients
Novel compounds that target spreading bacterial biofilms that negatively impact lung functions.
Research & publications
Sequoia’s research and development studies and programs have been published in more than 50 peer-reviewed scientific publications. We invite you to learn more about our science.
View publications